Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 19 peer-reviewed journal articles Updated
Pulmonology · Alpha-1 Antitrypsin Deficiency

The Path to Diagnosis: Navigating the Long Road to Answers

At a Glance

Alpha-1 Antitrypsin Deficiency (AATD) is often misdiagnosed as asthma or COPD, leading to an average diagnostic delay of 5.6 to 7 years. This delay can worsen lung function, making it crucial to get specific genetic testing if respiratory or liver symptoms do not respond to standard treatments.

For many people with Alpha-1 Antitrypsin Deficiency (AATD), the path to a correct diagnosis is not a straight line, but a long and often frustrating journey known as a “diagnostic odyssey” [1][2]. It is common to feel a sense of relief mixed with anger when you finally learn the cause of your symptoms after years of being told it was “just asthma” or “smoker’s lung” [3][4].

The Reality of Diagnostic Delay

Research shows that the average time from the first appearance of symptoms to an accurate diagnosis of AATD is approximately 5.6 to 7 years, though for some, it can take a decade or longer [1][5]. During this time, patients often consult multiple physicians before the correct testing is finally performed [1][5].

This delay is not just a matter of frustration; it has measurable impacts on health:

  • Worsening Symptoms: For every year the diagnosis is delayed, patients report significantly worse respiratory symptoms and a lower functional status on standardized health tests [6].
  • Loss of Lung Function: There is a documented trend where each year of delay correlates with a decrease in FEV1 (Forced Expiratory Volume in one second), a key measure of how much air you can breathe out [6].
  • Missed Opportunities: A late diagnosis means a delay in starting specialized treatments, such as augmentation therapy, which is most effective when started before irreversible lung damage occurs [7][8].

Why is Alpha-1 Often Misdiagnosed?

AATD is frequently referred to as a “great masquerader” because its symptoms are identical to more common conditions [3][4].

Common “Masquerades”:

  1. Asthma: Because AATD can cause wheezing and shortness of breath, many patients are initially treated for asthma [3][9]. Unlike typical asthma, however, the symptoms of AATD-related lung disease are often progressive and do not fully resolve with standard inhalers [7][4].
  2. Smoking-Related COPD: Doctors may assume that lung damage is solely due to a history of smoking [3][4]. While smoking significantly accelerates AATD, the underlying genetic deficiency makes the lungs far more vulnerable than those of a typical smoker [10][11].
  3. Unexplained Liver Disease: In adults, AATD can manifest as “cryptogenic” (unexplained) cirrhosis or fatty liver disease [12][13]. In children, it can present in infancy as prolonged neonatal jaundice [14]. Without specific genetic testing, the root cause may remain a mystery for years [3][15].

Early Warning Signs

The symptoms that eventually drive “Alphas” to the doctor often start subtly and may include:

  • Dyspnea: Shortness of breath, especially during physical activity [16].
  • Persistent Cough: A chronic cough that may produce phlegm [16].
  • Wheezing: A whistling sound when breathing [16].
  • Decreased Exercise Tolerance: Finding it harder to keep up with daily tasks or exercise routines [6].
  • Jaundice or Swelling: In cases of liver involvement, symptoms may include yellowing of the skin or eyes and swelling in the abdomen or legs [12].

Validating Your Experience

If you spent years seeking answers, your feelings of frustration are valid. The delay is often due to a lack of awareness among healthcare providers rather than a lack of symptoms [17][5]. Understanding that AATD was the missing piece of the puzzle is the first step toward taking control of your health and accessing the specialized care you deserve [18][19].

Common questions in this guide

Why does it take so long to get diagnosed with Alpha-1?
Alpha-1 is often called a 'great masquerader' because its early symptoms are nearly identical to more common conditions like asthma or smoking-related COPD. Because of this, it takes an average of 5.6 to 7 years for patients to receive the correct genetic testing.
How do I know if my asthma is actually Alpha-1?
Unlike typical asthma, the lung symptoms caused by Alpha-1 are often progressive and do not fully improve with standard asthma inhalers. If you have chronic shortness of breath or wheezing that doesn't respond to typical treatments, ask your doctor about AATD testing.
What happens if my AATD diagnosis is delayed?
A delayed diagnosis can lead to worsening respiratory symptoms and a continued loss of lung function over time. It also delays the start of specialized treatments like augmentation therapy, which is most effective when started before irreversible lung damage occurs.
What questions should I ask my doctor after finally getting an AATD diagnosis?
You should ask your doctor to establish a baseline for your lung and liver health using tests like a high-resolution CT scan or FibroScan. It is also important to discuss if your previous asthma or COPD treatments need adjusting and if you are a candidate for augmentation therapy.

Questions For You

Answer a question to get research tailored to you. Your answers are private.

Related questions

What is a Safe Indoor AQI Level for Alpha-1 (AATD)? What Mask Should Alpha-1 Patients Wear for Wildfire Smoke? How to Test for Alpha-1 if Misdiagnosed with Asthma Should You Evacuate for Wildfire Smoke with Alpha-1?

Get notified when new evidence is published on Alpha-1-antitrypsin deficiency.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.How long has my AATD likely been progressing based on my current lung function and imaging?
  2. 2.Is my current treatment plan for asthma or COPD still appropriate, or should it be adjusted now that we know the underlying cause?
  3. 3.What specific tests (like a high-resolution CT or FibroScan) do I need to establish a 'baseline' for my lung and liver health?
  4. 4.Given the delay in my diagnosis, am I a candidate for augmentation therapy to slow further damage?
  5. 5.Can you recommend a specialist, such as a pulmonologist or hepatologist, who has specific experience managing Alpha-1?

References

References (19)
  1. 1

    Pathophysiology of Alpha-1 Antitrypsin Lung Disease.

    Kalfopoulos M, Wetmore K, ElMallah MK

    Methods in molecular biology (Clifton, N.J.) 2017; (1639()):9-19 doi:10.1007/978-1-4939-7163-3_2.

    PMID: 28752442
  2. 2

    Suspecting and Testing for Alpha-1 Antitrypsin Deficiency-An Allergist's and/or Immunologist's Perspective.

    Craig TJ

    The journal of allergy and clinical immunology. In practice 2015; (3(4)):506-11.

    PMID: 26032475
  3. 3

    The important role of primary care providers in the detection of alpha-1 antitrypsin deficiency.

    Lascano JE, Campos MA

    Postgraduate medicine 2017; (129(8)):889-895 doi:10.1080/00325481.2017.1381539.

    PMID: 28929906
  4. 4

    Alpha-1 antitrypsin deficiency in the elderly: a case report.

    Annunziata A, Lanza M, Coppola A, Fiorentino G

    Journal of medical case reports 2021; (15(1)):231 doi:10.1186/s13256-021-02847-w.

    PMID: 33966640
  5. 5

    Detecting Alpha-1 Antitrypsin Deficiency.

    Stoller JK

    Annals of the American Thoracic Society 2016; (13 Suppl 4()):S317-25 doi:10.1513/AnnalsATS.201506-349KV.

    PMID: 27564667
  6. 6

    The Impact of Delayed Diagnosis of Alpha-1 Antitrypsin Deficiency: The Association Between Diagnostic Delay and Worsened Clinical Status.

    Tejwani V, Nowacki AS, Fye E, et al.

    Respiratory care 2019; (64(8)):915-922 doi:10.4187/respcare.06555.

    PMID: 30914495
  7. 7

    Long-term clinical outcomes following treatment with alpha 1-proteinase inhibitor for COPD associated with alpha-1 antitrypsin deficiency: a look at the evidence.

    Rahaghi FF, Miravitlles M

    Respiratory research 2017; (18(1)):105 doi:10.1186/s12931-017-0574-1.

    PMID: 28558837
  8. 8

    Alpha 1 antitrypsin to treat lung disease in alpha 1 antitrypsin deficiency: recent developments and clinical implications.

    Chapman KR, Chorostowska-Wynimko J, Koczulla AR, et al.

    International journal of chronic obstructive pulmonary disease 2018; (13()):419-432 doi:10.2147/COPD.S149429.

    PMID: 29430176
  9. 9

    Alpha-1 Antitrypsin Replacement in Patients With COPD.

    Wells AD, Woods A, Hilleman DE, Malesker MA

    P & T : a peer-reviewed journal for formulary management 2019; (44(7)):412-415.

    PMID: 31258312
  10. 10

    [Alpha 1-antitrypsin deficiency].

    Mornex JF

    Revue des maladies respiratoires 2022; (39(8)):698-707 doi:10.1016/j.rmr.2022.02.062.

    PMID: 35715315
  11. 11

    Pulmonary manifestations of alpha 1 antitrypsin deficiency.

    Mulkareddy V, Roman J

    The American journal of the medical sciences 2024; (368(1)):1-8 doi:10.1016/j.amjms.2024.04.002.

    PMID: 38599244
  12. 12

    Practical dietary advices for subjects with alpha-1 antitrypsin deficiency.

    Rondanelli M, Gasparri C, Razza C, et al.

    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2023; (163()):114753 doi:10.1016/j.biopha.2023.114753.

    PMID: 37119738
  13. 13

    Intravenous Alpha-1 Antitrypsin Therapy for Alpha-1 Antitrypsin Deficiency: The Current State of the Evidence.

    Brantly ML, Lascano JE, Shahmohammadi A

    Chronic obstructive pulmonary diseases (Miami, Fla.) 2018; (6(1)):100-114 doi:10.15326/jcopdf.6.1.2017.0185.

    PMID: 30775428
  14. 14

    Liver Involvement in Children with Alpha-1 Antitrypsin Deficiency: A Multicenter Study.

    Cakir M, Sag E, Islek A, et al.

    Pediatric gastroenterology, hepatology & nutrition 2020; (23(2)):146-153 doi:10.5223/pghn.2020.23.2.146.

    PMID: 32206627
  15. 15

    Detection of alpha-1 antitrypsin deficiency: the past, present and future.

    Brantly M, Campos M, Davis AM, et al.

    Orphanet journal of rare diseases 2020; (15(1)):96 doi:10.1186/s13023-020-01352-5.

    PMID: 32306990
  16. 16

    Alpha-1 Asthma Overlap Syndrome: a Clinical Overview.

    Izquierdo M, Rawal H, Armstrong M, Marion CR

    Current allergy and asthma reports 2022; (22(9)):101-111 doi:10.1007/s11882-022-01036-z.

    PMID: 35596100
  17. 17

    Can Proteomics Play a Significant Role in the Identification of Biomarkers for Alpha1-Antitrypsin Deficiency?

    Grignano MA, D'Amato M, Gregorini M, et al.

    International journal of molecular sciences 2025; (26(11)) doi:10.3390/ijms26115085.

    PMID: 40507896
  18. 18

    An Epidemiological Overview of Chronic Obstructive Pulmonary Disease: What Can Real-Life Data Tell Us about Disease Management?

    Soriano JB

    COPD 2017; (14(sup1)):S3-S7 doi:10.1080/15412555.2017.1286165.

    PMID: 28306356
  19. 19

    Alpha-1 antitripsyn deficiency and augmentation therapy in pregnancy: two case reports.

    Annunziata A, Fiorentino G, Coppola A, et al.

    Frontiers in medicine 2024; (11()):1479877 doi:10.3389/fmed.2024.1479877.

    PMID: 39736979

This page is for informational purposes only and does not replace professional medical advice. Always consult your pulmonologist or hepatologist about your specific AATD diagnosis and treatment plan.